Effect of ARMS2 Gene Polymorphism on Intravitreal Ranibizumab Treatment for Neovascular Age-Related Macular Degeneration

Genetics and Molecular Research - Brazil
doi 10.4238/gmr15049164
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Genetics and Molecular Research

Related search

Ranibizumab Versus Verteporfin for Neovascular Age-Related Macular Degeneration

New England Journal of Medicine
Medicine
2006English

Peripapillary Choroidal Thickness After Intravitreal Ranibizumab Injections in Eyes With Neovascular Age-Related Macular Degeneration

BMC Ophthalmology
MedicineOphthalmology
2016English

Choroidal Blood Flow After the First Intravitreal Ranibizumab Injection in Neovascular Age-Related Macular Degeneration Patients

Acta Ophthalmologica
MedicineOphthalmology
2018English

Analysis of the Association Between CFH Y402H Polymorphism and Response to Intravitreal Ranibizumab in Patients With Neovascular Age-Related Macular Degeneration (nAMD)

Bosnian Journal of Basic Medical Sciences
Medicine
2018English

Patterns of Early and Delayed Visual Response to Ranibizumab Treatment for Neovascular Age-Related Macular Degeneration

JAMA Ophthalmology
Ophthalmology
2016English

Intravitreal Bevacizumab vs Verteporfin Photodynamic Therapy for Neovascular Age-Related Macular Degeneration

Archives of Ophthalmology
2007English

Safety and Efficacy of Ranibizumab and Bevacizumab for the Treatment of Neovascular Age-Related Macular Degeneration

European Ophthalmic Review
2012English

Ranibizumab Monotherapy in Neovascular Age-Related Macular Degeneration With Pigment Epithelial Detachment

Journal of Clinical & Experimental Ophthalmology
2012English

Ranibizumab in Neovascular Age-Related Macular Degeneration: A 5-Year Follow-Up

Clinical Ophthalmology
Ophthalmology
2016English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy